Drug intelligence / Profile preview

ARVN603

Development stage: Preclinical
Lead developer: Arctic Vision
Modality: Gene Therapies
Administration: Intravitreal

Overview

ARVN603 (also known as ARVN-603) is an adeno-associated virus (AAV)-based gene therapy being developed by Arctic Vision for the treatment of inherited retinal degeneration. The therapeutic candidate is designed to deliver a functional copy of a target gene to retinal cells to address genetic mutations that lead to retinal degeneration. ARVN603 is currently in preclinical development.

Beyond the preview

Go deeper on ARVN603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARVN603.

Explore the full profile